$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd

$irwd Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000155837021001136 Filed on February 17, 2021

Income Statement

Concept	2019 Q4	2019 Q3	2019 Q2
Revenue	$126.3M	$131.2M	$102.2M
YoY Change	-3.36%	99.69%	26.03%
Cost Of Revenue	$11.00M	$506.0K	$11.31M
YoY Change	-48.84%	-89.04%	178.3%
Gross Profit	$115.3M	$130.7M	$90.90M
YoY Change	5.59%	113.95%	17.99%
Gross Profit Margin	91.29%	99.61%	88.93%
Selling, General & Admin	$39.20M	$40.92M	$43.25M
YoY Change	-22.38%	-19.03%	-27.65%
% of Gross Profit	34.0%	31.32%	47.57%
Research & Development	$26.50M	$27.55M	$28.76M
YoY Change	-6.03%	-5.51%	24.03%
% of Gross Profit	22.98%	21.09%	31.64%
Depreciation & Amortization	$900.0K	$3.200M	$300.0K
YoY Change	-30.77%	33.33%	-94.23%
% of Gross Profit	0.78%	2.45%	0.33%
Operating Expenses	$65.70M	$68.47M	$72.00M
YoY Change	-16.52%	-14.08%	-13.2%
Operating Profit	$49.60M	$65.89M	$21.58M
YoY Change	62.62%	-144.95%	-247.01%
Interest Expense	-$2.000M	$10.46M	$9.430M
YoY Change	-90.7%	10.28%	0.5%
% of Operating Profit	-4.03%	15.87%	43.7%
Other Income/Expense, Net	-$1.735M	-$45.24M	-$9.294M
YoY Change	-91.93%	761.37%	-1.75%
Pretax Income	$47.90M	$20.65M	$12.30M
YoY Change	470.24%	-113.6%	-151.04%
Income Tax
% Of Pretax Income
Net Earnings	$47.86M	$20.65M	$12.28M
YoY Change	-408.9%	-111.84%	-124.87%
Net Earnings / Revenue	37.89%	15.74%	12.02%
Basic Earnings Per Share	$0.31	$0.13	$0.08
Diluted Earnings Per Share	$0.30	$0.13	$0.08
COMMON SHARES
Basic Shares Outstanding	156.8M	156.4K	155.8K
Diluted Shares Outstanding		156.8K	155.8K

Balance Sheet

Concept	2019 Q4	2019 Q3	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$177.0M	$139.2M	$98.90M
YoY Change	2.19%	-13.75%	-45.42%
Cash & Equivalents	$177.0M	$139.2M	$98.91M
Short-Term Investments
Other Short-Term Assets	$12.00M	$19.60M	$16.60M
YoY Change	-3.23%	-9.68%	-0.6%
Inventory	$648.0K	$2.298M	$1.735M
Prepaid Expenses
Receivables	$11.28M	$2.017M	$22.60M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$306.9M	$257.6M	$221.0M
YoY Change	15.17%	3.68%	-20.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.43M	$11.38M	$6.665M
YoY Change	62.43%	-29.75%	-59.11%
Goodwill	$785.0K	$785.0K	$785.0K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$790.0K	$20.00K	$26.00K
YoY Change	787.64%	-99.99%	-99.98%
Total Long-Term Assets	$95.90M	$76.71M	$94.74M
YoY Change	46.15%	-54.4%	-72.03%
TOTAL ASSETS
Total Short-Term Assets	$306.9M	$257.6M	$221.0M
Total Long-Term Assets	$95.90M	$76.71M	$94.74M
Total Assets	$402.7M	$334.3M	$315.7M
YoY Change	21.29%	-19.76%	-48.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.978M	$4.505M	$7.872M
YoY Change	-73.29%	-51.56%	-66.92%
Accrued Expenses	$34.60M	$45.40M	$52.20M
YoY Change	-35.33%	-9.2%	20.83%
Deferred Revenue	$875.0K	$1.278M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$48.80M
YoY Change	-100.0%	-100.0%	78.75%
Total Short-Term Liabilities	$40.93M	$52.80M	$110.9M
YoY Change	-65.76%	-53.11%	16.7%
LONG-TERM LIABILITIES
Long-Term Debt	$408.0M	$402.7M	$352.7M
YoY Change	11.38%	8.87%	-7.14%
Other Long-Term Liabilities	$734.0K	$492.0K	$2.626M
YoY Change	-70.99%	-99.63%	-98.6%
Total Long-Term Liabilities	$734.0K	$492.0K	$2.626M
YoY Change	-70.99%	-99.9%	-99.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$40.93M	$52.80M	$110.9M
Total Long-Term Liabilities	$734.0K	$492.0K	$2.626M
Total Liabilities	$41.66M	$53.29M	$113.5M
YoY Change	-65.87%	-91.32%	-82.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.572B	-$1.620B	-$1.641B
YoY Change	-1.19%
Common Stock	$1.479B	$1.467B	$1.421B
YoY Change	6.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$93.25M	-$153.0M	-$219.4M
YoY Change
Total Liabilities & Shareholders Equity	$402.7M	$334.3M	$315.7M
YoY Change	21.29%	-19.76%	-48.93%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2019 Q2
OPERATING ACTIVITIES
Net Income	$47.86M	$20.65M	$12.28M
YoY Change	-408.9%	-111.84%	-124.87%
Depreciation, Depletion And Amortization	$900.0K	$3.200M	$300.0K
YoY Change	-30.77%	33.33%	-94.23%
Cash From Operating Activities	$27.60M	$34.70M	-$9.200M
YoY Change	196.77%	-230.45%	-59.47%
INVESTING ACTIVITIES
Capital Expenditures	-$2.700M	-$3.100M	$1.800M
YoY Change	-18.18%	47.62%	-205.88%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$4.300M
YoY Change	-100.0%	-100.0%	-130.5%
Cash From Investing Activities	-$2.600M	-$3.100M	-$2.400M
YoY Change	-114.86%	-121.68%	-119.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.400M	8.700M	-7.500M
YoY Change	30.61%	11.54%	-161.98%
NET CHANGE
Cash From Operating Activities	27.60M	34.70M	-9.200M
Cash From Investing Activities	-2.600M	-3.100M	-2.400M
Cash From Financing Activities	6.400M	8.700M	-7.500M
Net Change In Cash	31.40M	40.30M	-19.10M
YoY Change	-0.95%	-995.56%	-1161.11%
FREE CASH FLOW
Cash From Operating Activities	$27.60M	$34.70M	-$9.200M
Capital Expenditures	-$2.700M	-$3.100M	$1.800M
Free Cash Flow	$30.30M	$37.80M	-$11.00M
YoY Change	140.48%	-254.29%	-47.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	106176000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	21505000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-282368000
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3345000
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	25204000
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	34423000
CY2020Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	43204000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	106176000
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-59284000
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	12283000
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	20648000
CY2019Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	47858000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	21505000
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0
CY2019	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0
CY2020	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0
CY2018	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	0
CY2019	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	0
CY2020	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	0
CY2019	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	0
CY2018	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	0
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	160616675
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	157535962
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1250000
CY2020Q4	us-gaap	Derivative Asset Valuation Technique Extensible List DerivativeAssetValuationTechniqueExtensibleList	us-gaap:ValuationTechniqueOptionPricingModelMember
CY2020Q4	us-gaap	Derivative Liability Valuation Technique Extensible List DerivativeLiabilityValuationTechniqueExtensibleList	us-gaap:ValuationTechniqueOptionPricingModelMember
CY2019Q4	us-gaap	Derivative Asset Valuation Technique Extensible List DerivativeAssetValuationTechniqueExtensibleList	us-gaap:ValuationTechniqueOptionPricingModelMember
CY2019Q4	us-gaap	Derivative Liability Valuation Technique Extensible List DerivativeLiabilityValuationTechniqueExtensibleList	us-gaap:ValuationTechniqueOptionPricingModelMember
CY2020	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001446847
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-34620
CY2020	dei	Entity Registrant Name EntityRegistrantName	IRONWOOD PHARMACEUTICALS, INC.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3404176
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Summer Street
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2300
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02110
CY2020	dei	City Area Code CityAreaCode	617
CY2020	dei	Local Phone Number LocalPhoneNumber	621-7722
CY2020	dei	Security12b Title Security12bTitle	Class A Common Stock, $0.001 par value
CY2020	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.001
CY2020	dei	Trading Symbol TradingSymbol	IRWD
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	1634804172
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	160962175
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	362564000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177023000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	122351000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11279000
CY2019Q4	us-gaap	Related Party Transaction Due From To Related Party Current RelatedPartyTransactionDueFromToRelatedPartyCurrent	105967000
CY2019Q4	us-gaap	Inventory Net InventoryNet	648000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9189000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10685000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1735000
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1250000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	495839000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	306852000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	485000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	971000
CY2020Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	23401000
CY2019Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	32597000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8929000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12429000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16576000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17743000
CY2020Q4	us-gaap	Hedging Assets Noncurrent HedgingAssetsNoncurrent	13065000
CY2019Q4	us-gaap	Hedging Assets Noncurrent HedgingAssetsNoncurrent	31366000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	943000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	790000
CY2020Q4	us-gaap	Assets Assets	559238000
CY2019Q4	us-gaap	Assets Assets	402748000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	661000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3978000
CY2019Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	1509000
CY2020Q4	irwd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1898000
CY2019Q4	irwd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	2956000
CY2020Q4	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	26486000
CY2019Q4	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	30465000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3128000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1146000
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	875000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32173000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40929000
CY2020Q4	us-gaap	Hedging Liabilities Noncurrent HedgingLiabilitiesNoncurrent	12088000
CY2019Q4	us-gaap	Hedging Liabilities Noncurrent HedgingLiabilitiesNoncurrent	24260000
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	430256000
CY2019Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	407994000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20318000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22082000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1763000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	734000
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	160616675
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	157535962
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	161000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	158000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1528535000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1478823000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1466056000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1572232000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	62640000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-93251000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	559238000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	402748000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	389523000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	428413000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	346639000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3136000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	23875000
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	32751000
CY2019	irwd	Inventory Write Down Of Net Realizable Value And Loss On Non Cancellable Purchase Commitments InventoryWriteDownOfNetRealizableValueAndLossOnNonCancellablePurchaseCommitments	-3530000
CY2018	irwd	Inventory Write Down Of Net Realizable Value And Loss On Non Cancellable Purchase Commitments InventoryWriteDownOfNetRealizableValueAndLossOnNonCancellablePurchaseCommitments	247000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	88062000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	115044000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	101060000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	140003000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	172450000
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	219676000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8111000
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-31045000
CY2019	irwd	Gain Loss On Modification Of Lease GainLossOnModificationOfLease	3169000
CY2020	us-gaap	Restructuring Charges RestructuringCharges	15382000
CY2019	us-gaap	Restructuring Charges RestructuringCharges	3620000
CY2018	us-gaap	Restructuring Charges RestructuringCharges	14715000
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	151794000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	246583000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	308290000
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	497309000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	142940000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	120123000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-150670000
CY2020	us-gaap	Interest Expense InterestExpense	29478000
CY2019	us-gaap	Interest Expense InterestExpense	36602000
CY2018	us-gaap	Interest Expense InterestExpense	37724000
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	1504000
CY2019	us-gaap	Investment Income Net InvestmentIncomeNet	2862000
CY2018	us-gaap	Investment Income Net InvestmentIncomeNet	2991000
CY2020	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-6129000
CY2019	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	3023000
CY2018	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-8743000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-30977000
CY2020	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	24000
CY2019	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	514000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-34079000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-61180000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-43476000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	108861000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	58943000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-194146000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2685000
CY2020	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	106176000
CY2019	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	58943000
CY2018	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-194146000
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-37438000
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-88222000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	106176000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	21505000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-282368000
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.67
CY2019	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.38
CY2018	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.27
CY2020	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.66
CY2019	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.38
CY2018	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.27
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.24
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.58
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.67
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.85
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.66
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.85
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	159427000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	156023000
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	152634000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	160655000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	156023000
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	152634000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	106176000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	21505000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-282368000
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	79000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	79000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	106176000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	21505000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-282289000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	9848000
CY2018	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	32061000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	44009000
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	79000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-282368000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-196371000
CY2018	irwd	Stock Issued During Period Value Share Based Awards And Employee Stock Purchase Plan Net Of Cancellations StockIssuedDuringPeriodValueShareBasedAwardsAndEmployeeStockPurchasePlanNetOfCancellations	13601000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32331000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	92502000
CY2019	irwd	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Issuance Costs AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtIssuanceCosts	2092000
CY2019	irwd	Adjustments To Additional Paid In Capital Purchase Of Capped Calls AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls	25159000
CY2019	irwd	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Repurchases AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRepurchases	26959000
CY2019	us-gaap	Dividends Dividends	2609000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	21505000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-93251000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-93251000
CY2020	irwd	Stock Issued During Period Value Stock Options Exercised And Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueStockOptionsExercisedAndValueEmployeeStockPurchasePlan	18540000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31175000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	106176000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	62640000
CY2020	us-gaap	Profit Loss ProfitLoss	106176000
CY2019	us-gaap	Profit Loss ProfitLoss	21505000
CY2018	us-gaap	Profit Loss ProfitLoss	-282368000
CY2020	us-gaap	Depreciation Depreciation	3564000
CY2019	us-gaap	Depreciation Depreciation	5580000
CY2018	us-gaap	Depreciation Depreciation	3859000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8111000
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	151794000
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-470000
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-146000
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1867000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	31175000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	31278000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	40526000
CY2019	irwd	Gain Loss On Modification Of Lease GainLossOnModificationOfLease	3169000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-12172000
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	16232000
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-58425000
CY2020	irwd	Fair Value Adjustment Of Convertible Note Hedging Instrument FairValueAdjustmentOfConvertibleNoteHedgingInstrument	18301000
CY2019	irwd	Fair Value Adjustment Of Convertible Note Hedging Instrument FairValueAdjustmentOfConvertibleNoteHedgingInstrument	-19255000
CY2018	irwd	Fair Value Adjustment Of Convertible Note Hedging Instrument FairValueAdjustmentOfConvertibleNoteHedgingInstrument	67168000
CY2019	irwd	Inventory Write Down Of Net Realizable Value And Loss Settlement On Non Cancellable Purchase Commitments InventoryWriteDownOfNetRealizableValueAndLossSettlementOnNonCancellablePurchaseCommitments	-3530000
CY2018	irwd	Inventory Write Down Of Net Realizable Value And Loss Settlement On Non Cancellable Purchase Commitments InventoryWriteDownOfNetRealizableValueAndLossSettlementOnNonCancellablePurchaseCommitments	219000
CY2018	irwd	Purchase Commitment Write Down Sample Supply PurchaseCommitmentWriteDownSampleSupply	390000
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	165000
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	22263000
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	19590000
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	17601000
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-31045000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-30977000
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-4091000
CY2019	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	68893000
CY2018	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-1207000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-648000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	806000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1515000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1046000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3727000
CY2020	irwd	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-1167000
CY2019	irwd	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-14141000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	153000
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-159000
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-702000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7523000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-32700000
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2678000
CY2020	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	-1058000
CY2019	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	-483000
CY2018	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	542000
CY2020	irwd	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	218000
CY2019	irwd	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-12046000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-875000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	875000
CY2018	irwd	Increase Decrease In Deferred Rent Payables IncreaseDecreaseInDeferredRentPayables	916000
CY2020	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1029000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	168836000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-639000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-82690000
CY2019	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	11364000
CY2018	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	11808000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	168836000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10725000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-70882000
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	3241000
CY2018	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	99165000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1842000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7189000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	351000
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	268000
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1563000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1842000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6921000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	97136000
CY2019	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-4223000
CY2018	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-8270000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1842000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11144000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	88866000
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	400000000
CY2019	irwd	Purchase Of Capped Calls PurchaseOfCappedCalls	25159000
CY2019	irwd	Proceeds From Partial Termination Of Convertible Note Hedges And Warrants ProceedsFromPartialTerminationOfConvertibleNoteHedgesAndWarrants	3174000
CY2019	irwd	Payments Of Convertible Debt Issuance Costs PaymentsOfConvertibleDebtIssuanceCosts	9048000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	18546000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13595000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	32061000
CY2018	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1824000
CY2019	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	227338000
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	156409000
CY2018	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	165000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	18546000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-1185000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	30072000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18546000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1185000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30072000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	185540000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1604000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	48056000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179244000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	180848000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132792000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	364784000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179244000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	180848000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	362564000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177023000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	173172000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	2220000
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	2221000
CY2018Q4	us-gaap	Restricted Cash RestrictedCash	7676000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	364784000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179244000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	180848000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	7216000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	17584000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	18235000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1848000
CY2018	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	664000
CY2018	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1	2687000
CY2019Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	486000
CY2019	irwd	Fixed Assets In Accounts Payable And Accrued Expenses FixedAssetsInAccountsPayableAndAccruedExpenses	1282000
CY2018	irwd	Fixed Assets In Accounts Payable And Accrued Expenses FixedAssetsInAccountsPayableAndAccruedExpenses	439000
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">1. Nature of Business </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Ironwood Pharmaceuticals, Inc. (“Ironwood” or the “Company”) is a gastrointestinal (“GI”) healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for GI patients. The Company is focused on the development and commercialization of innovative GI product opportunities in areas of significant unmet need, leveraging its demonstrated expertise and capabilities in GI diseases. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">LINZESS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (linaclotide), the Company’s commercial product, is the first product approved by the United States Food and Drug Administration (the “U.S. FDA”) in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (“IBS-C”) or chronic idiopathic constipation (“CIC”). LINZESS is available to adult men and women suffering from IBS-C or CIC in the United States (the “U.S.”) and Mexico and to adult men and women suffering from IBS-C in Japan and China. Linaclotide is available under the trademarked name CONSTELLA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> to adult men and women suffering from IBS-C or CIC in Canada and to adult men and women suffering from IBS-C in certain European countries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has strategic partnerships with leading pharmaceutical companies to support the development and commercialization of linaclotide throughout the world. The Company and its partner, AbbVie Inc. (together with its affiliates, “AbbVie”) (successor to Allergan plc (together with its affiliates), “Allergan”), began commercializing LINZESS in the U.S. in December 2012. Under the Company’s collaboration with AbbVie for North America, total net sales of LINZESS in the U.S., as recorded by AbbVie, are reduced by commercial costs incurred by each party, and the resulting amount is shared equally between the Company and AbbVie. AbbVie also has an exclusive license from the Company to develop and commercialize linaclotide in all countries other than China (including Hong Kong and Macau), Japan and the countries and territories of North America (the “AbbVie License Territory”). On a country-by-country and product-by-product basis in the AbbVie License Territory, AbbVie pays the Company a royalty as a percentage of net sales of products containing linaclotide as an active ingredient. In addition, AbbVie has exclusive rights to commercialize linaclotide in Canada as CONSTELLA and in Mexico as LINZESS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Astellas Pharma Inc. (“Astellas”), the Company’s partner in Japan, has an exclusive license to develop and commercialize linaclotide in Japan. In March 2017, Astellas began commercializing LINZESS for the treatment of adults with IBS-C in Japan, and in September 2018, Astellas began commercializing LINZESS for the treatment of adults with chronic constipation in Japan. In August 2019, the Company amended and restated its license agreement with Astellas. Effective in 2020, Company is no longer responsible for the supply of linaclotide active pharmaceutical ingredient (“API”) to Astellas (Note 6). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In October 2012, the Company and AstraZeneca AB (together with its affiliates) (“AstraZeneca”) entered into a collaboration agreement to co-develop and co-commercialize linaclotide in China (including Hong Kong and Macau) (the “AstraZeneca License Territory”). In September 2019, the Company amended and restated its existing collaboration agreement with AstraZeneca whereby AstraZeneca obtained the exclusive right to develop, manufacture, and commercialize products containing linaclotide in the AstraZeneca License Territory (Note 6). In November 2019, AstraZeneca began commercializing LINZESS for the treatment of adults with IBS-C in China. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company and AbbVie are exploring ways to enhance the clinical profile of LINZESS by studying linaclotide in additional indications, populations and formulations to assess its potential to treat various conditions. In September 2020, based on the Phase IIIb data demonstrating efficacy and safety of LINZESS 290 mcg on the overall abdominal symptoms of bloating, pain and discomfort in adult patients with IBS-C, the U.S. FDA approved the Company’s Supplemental New Drug Application to include a more comprehensive description of the effects of LINZESS in its approved label. In June 2020 and July 2020, the United States Patent and Trademark Office granted patents covering the formulation of the 72 mcg dose of LINZESS and methods of using the formulation, respectively. The patents are expected to expire in 2031.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company and AbbVie were developing MD-7246, a delayed release formulation of linaclotide. In May 2020, the Company and AbbVie announced top-line data from a Phase II trial evaluating MD-7246 in adult patients with </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">abdominal pain associated with irritable bowel syndrome with diarrhea. The Phase II trial did not meet its primary or key secondary endpoints. Based on these findings, the Company and AbbVie discontinued the development of MD-7246.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company was developing IW-3718, a gastric retentive formulation of a bile acid sequestrant, in a Phase III program. In September 2020, the Company announced that one of its two identical Phase III trials for the potential treatment of refractory gastroesophageal reflux disease (“refractory GERD”) did not meet the pre-specified criteria associated with a planned early efficacy assessment. Based on these findings, the Company is discontinuing development of IW-3718. In connection with this decision, the Company reduced its workforce by approximately 100 full-time employees. This workforce reduction affected both field-based and home-office employees, including the relevant general and administrative support functions. The Company substantially completed the reduction in its workforce in the fourth quarter of 2020 (Note 18).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, the Company periodically enters into co-promotion agreements to bolster its salesforce productivity. In August 2019, the Company entered into a disease education and promotional agreement with Alnylam Pharmaceuticals, Inc. (“Alnylam”) for Alnylam’s GIVLAARI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (givosiran) for the treatment of acute hepatic porphyria (“AHP”). Under the agreement, the Company performs disease awareness activities related to AHP and sales detailing activities of GIVLAARI. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">These and other agreements are more fully described in Note 6, <i style="font-style:italic;">Collaboration, License, Co-Promotion and Other Commercial Agreements,</i> to these consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On April 1, 2019, Ironwood completed the separation (the “Separation”) of its soluble guanylate cyclase (“sGC”) business, and certain other assets and liabilities, into Cyclerion Therapeutics, Inc (“Cyclerion”). The Separation was effected by means of a distribution of all of the outstanding shares of common stock, with no par value, of Cyclerion through a dividend of all outstanding shares of Cyclerion’s common stock, to Ironwood’s stockholders of record as of the close of business on March 19, 2019 (Note 3). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was incorporated in Delaware on January 5, 1998 as Microbia, Inc. On April 7, 2008, the Company changed its name to Ironwood Pharmaceuticals, Inc. To date, the Company has dedicated a majority of its activities to the research, development and commercialization of linaclotide, as well as to the research and development of its other product candidates. Prior to the year ended December 31, 2019, the Company incurred net losses in each year since its inception in 1998. For the years ended December 31, 2020 and 2019, the Company recorded net income of approximately $106.2 million and approximately $21.5 million, respectively. As of December 31, 2020, the Company had an accumulated deficit of approximately $1.5 billion.</p>
CY2020	us-gaap	Net Income Loss NetIncomeLoss	106200000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	21500000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1500000000
CY2018	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2019	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2020	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Reclassifications </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Certain prior period financial statement items have been reclassified to conform to current period presentation.</p>
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of revenues and expenses during the reported periods. On an ongoing basis, the Company’s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue recognition; accounts receivable; inventory valuation and related reserves; useful lives of long-lived assets, impairment of long-lived assets, including its acquired intangible assets and goodwill; valuation procedures for right-of-use assets and operating lease liabilities; valuation procedures for the issuance and repurchase of convertible notes; balance sheet classification of convertible notes; valuation of assets and liabilities held for disposition and losses related to discontinued operations; fair value of derivatives; income taxes, including the valuation allowance for deferred tax assets; research and development expenses; contingencies and share-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	349000000.0
CY2019Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	177000000.0
CY2020	us-gaap	Lease Practical Expedients Package LeasePracticalExpedientsPackage	true
CY2020Q4	us-gaap	Lease Practical Expedient Lessor Single Lease Component LeasePracticalExpedientLessorSingleLeaseComponent	true
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	2200000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	2200000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1700000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	500000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1000000.0
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentrations of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, restricted cash, and accounts receivable. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and the Company believes that such funds are subject to minimal credit risk. The Company has adopted an investment policy which limits the amounts the Company may invest in certain types of investments, and requires all investments held by the Company to be at least AA- rated, thereby reducing credit risk exposure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable primarily consist of amounts due under the linaclotide collaboration agreement with AbbVie for North America (Note 6). The Company does not obtain collateral for its accounts receivable. The Company previously reflected amounts due from Allergan, net of amounts payable to Allergan, prior to its acquisition by AbbVie as related party accounts receivable, net. Following the acquisition of Allergan by AbbVie, the Company determined that AbbVie is not a related party to the Company (Note 17).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The percentages of revenue recognized from significant collaborative partners of the Company in the years ended December 31, 2020, 2019 and 2018 as well as the account receivable balances, net of any payables due, at December 31, 2020 and 2019 are included in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="3" style="vertical-align:bottom;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accounts<br/>Receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Collaborative Partner:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">AbbVie (North America and Europe)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Astellas (Japan)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For the years ended December 31, 2020, 2019 and 2018, no additional customers accounted for more than 10% of the Company’s revenue.</p>
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	151800000
CY2020	us-gaap	Revenue Practical Expedient Incremental Cost Of Obtaining Contract RevenuePracticalExpedientIncrementalCostOfObtainingContract	true
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	106176000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	21505000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-282368000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	159427000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	156023000
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	152634000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	160655000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	156023000
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	152634000
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.67
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.85
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.66
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.85
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	58554000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	67087000
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	64080000
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	13065000
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	12088000
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	145800000
CY2020Q4	irwd	Accounts Receivable Net Of Accounts Payable Current And Noncurrent AccountsReceivableNetOfAccountsPayableCurrentAndNoncurrent	110900000
CY2019Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	43900000
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	900000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0
CY2020Q4	irwd	Threshold Percentage Of Collateralized Value ThresholdPercentageOfCollateralizedValue	1.02
CY2020Q4	irwd	Threshold Percentage Of Collateralized Value ThresholdPercentageOfCollateralizedValue	1.02
CY2019	irwd	Fair Value Transfer Between Measurement Levels FairValueTransferBetweenMeasurementLevels	0
CY2020	irwd	Fair Value Transfer Between Measurement Levels FairValueTransferBetweenMeasurementLevels	0
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	41020000
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	33763000
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	28909000
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	25735000
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	19255000
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	16232000
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	31366000
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	24260000
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-18301000
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-12172000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	2530000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	16452000
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	1526000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1420000
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1512000
CY2020	us-gaap	Lease Cost LeaseCost	3950000
CY2019	us-gaap	Lease Cost LeaseCost	19490000
CY2019	us-gaap	Sublease Income SubleaseIncome	300000
CY2019	irwd	Right Of Use Asset Obtained In Exchange For Operating Lease Liability Upon Adoption Of New Accounting Standard Codification RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityUponAdoptionOfNewAccountingStandardCodification	88299000
CY2019	irwd	Adjustment To Right Of Use Asset Lease Modification AdjustmentToRightOfUseAssetLeaseModification	-40427000
CY2019	irwd	Adjustment To Right Of Use Asset Lease Termination AdjustmentToRightOfUseAssetLeaseTermination	34440000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	18452000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1146000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	18598000
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y3M18D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y2M12D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3128000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3129000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3065000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3126000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3189000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	14856000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	30493000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7047000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	23446000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3128000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20318000
CY2020Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	1442000
CY2019Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	1260000
CY2020Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	10510000
CY2019Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	179000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2033000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	20734000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22511000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11805000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10082000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8929000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12429000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2300000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5600000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3900000
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	8719000
CY2019Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	11760000
CY2020Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	2625000
CY2019Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	2540000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	530000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1421000
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	627000
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2973000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10332000
CY2020Q4	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	26486000
CY2019Q4	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	30465000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2000000.0
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1600000
CY2020Q4	irwd	Other Accrued Liabilities Current Uninvoiced Vendor Liabilities OtherAccruedLiabilitiesCurrentUninvoicedVendorLiabilities	300000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10300000
CY2019Q4	irwd	Other Accrued Liabilities Current Goods Received But Not Yet Invoiced OtherAccruedLiabilitiesCurrentGoodsReceivedButNotYetInvoiced	4100000
CY2019Q4	irwd	Other Accrued Liabilities Current Move Activities OtherAccruedLiabilitiesCurrentMoveActivities	900000
CY2019Q4	irwd	Unbilled Inventories UnbilledInventories	600000
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	300000
CY2019Q4	irwd	Other Accrued Expenses Equipment For Clinical Studies OtherAccruedExpensesEquipmentForClinicalStudies	200000
CY2015Q2	us-gaap	Payments For Hedge Investing Activities PaymentsForHedgeInvestingActivities	21100000
CY2019Q3	us-gaap	Payments For Hedge Investing Activities PaymentsForHedgeInvestingActivities	25200000
CY2019Q3	irwd	Debt Instrument Conditional Conversion Repurchase Price Principal Percentage DebtInstrumentConditionalConversionRepurchasePricePrincipalPercentage	1
CY2019Q3	irwd	Debt Instrument Default Payment Percentage Of Principal Amount Of Notes Outstanding DebtInstrumentDefaultPaymentPercentageOfPrincipalAmountOfNotesOutstanding	0.25
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	7216000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	126557000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4500000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	203750000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	3000000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	201500000
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	546523000
CY2020Q4	irwd	Long Term Debt Maturities Interest Payments LongTermDebtMaturitiesInterestPayments	25824000
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	83900000
CY2020Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	6543000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	430256000
CY2015Q2	us-gaap	Payments Of Derivative Issuance Costs PaymentsOfDerivativeIssuanceCosts	21100000
CY2019Q3	irwd	Proceeds From Partial Termination Of Convertible Note Hedges And Warrants ProceedsFromPartialTerminationOfConvertibleNoteHedgesAndWarrants	3200000
CY2020Q4	irwd	Common Stock Voting Rights Per Share CommonStockVotingRightsPerShare	1
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31175000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31278000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	41082000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31175000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31278000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	41082000
CY2019	irwd	Allocated Share Based Compensation Expense Other Modifications AllocatedShareBasedCompensationExpenseOtherModifications	3000000.0
CY2020	irwd	Share Based Compensation Arrangements By Share Based Payment Award Options Expiration Term ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm	P10Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.89
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.10
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.81
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17194239
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.13
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M9D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	25226000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	55000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.84
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1735081
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.21
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	2054487
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	13.00
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13459671
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.25
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y3M7D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5613000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	13280456
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	12.26
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y2M23D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	5575000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	11963812
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	12.26
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M24D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5371000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3500000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5100000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	20100000
CY2020	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	2700000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	22861000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	4517000
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-59297000
CY2020	irwd	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Share Based Compensation Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingShareBasedCompensationAmount	74000
CY2019	irwd	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Share Based Compensation Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingShareBasedCompensationAmount	65000
CY2018	irwd	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Share Based Compensation Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingShareBasedCompensationAmount	218000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	7565000
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1902000
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-17121000
CY2019	irwd	Effective Income Tax Rate Reconciliation Disallowed Separation Related Costs EffectiveIncomeTaxRateReconciliationDisallowedSeparationRelatedCosts	4658000
CY2020	irwd	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	1718000
CY2019	irwd	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	662000
CY2018	irwd	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	8000
CY2020	irwd	Effective Income Tax Rate Reconciliation Meals And Entertainment EffectiveIncomeTaxRateReconciliationMealsAndEntertainment	395000
CY2019	irwd	Effective Income Tax Rate Reconciliation Meals And Entertainment EffectiveIncomeTaxRateReconciliationMealsAndEntertainment	495000
CY2018	irwd	Effective Income Tax Rate Reconciliation Meals And Entertainment EffectiveIncomeTaxRateReconciliationMealsAndEntertainment	995000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-144000
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1202000
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-494000
CY2020	irwd	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost Windfalls IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCostWindfalls	-5132000
CY2019	irwd	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost Windfalls IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCostWindfalls	-3324000
CY2018	irwd	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost Windfalls IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCostWindfalls	1223000
CY2020	irwd	Income Tax Reconciliation Fair Market Valuation Of Note Hedge Warrants And Convertible Note Hedges IncomeTaxReconciliationFairMarketValuationOfNoteHedgeWarrantsAndConvertibleNoteHedges	1680000
CY2019	irwd	Income Tax Reconciliation Fair Market Valuation Of Note Hedge Warrants And Convertible Note Hedges IncomeTaxReconciliationFairMarketValuationOfNoteHedgeWarrantsAndConvertibleNoteHedges	-290000
CY2018	irwd	Income Tax Reconciliation Fair Market Valuation Of Note Hedge Warrants And Convertible Note Hedges IncomeTaxReconciliationFairMarketValuationOfNoteHedgeWarrantsAndConvertibleNoteHedges	2367000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	3149000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	4374000
CY2018	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	7863000
CY2020	irwd	Income Tax Reconciliation Expiring Net Operating Losses And Tax Credits IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits	1991000
CY2019	irwd	Income Tax Reconciliation Expiring Net Operating Losses And Tax Credits IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits	3764000
CY2018	irwd	Income Tax Reconciliation Expiring Net Operating Losses And Tax Credits IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits	250000
CY2020	irwd	Income Tax Reconciliation Change In Enacted State And Local Tax Rates IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates	-208000
CY2019	irwd	Income Tax Reconciliation Change In Enacted State And Local Tax Rates IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates	-2563000
CY2018	irwd	Income Tax Reconciliation Change In Enacted State And Local Tax Rates IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates	1476000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-35230000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-7154000
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	80684000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2685000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	234772000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	265494000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	60607000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	59892000
CY2020Q4	irwd	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	7498000
CY2019Q4	irwd	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	9952000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	21848000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	24401000
CY2020Q4	irwd	Deferred Tax Assets Collaboration Agreement DeferredTaxAssetsCollaborationAgreement	62629000
CY2019Q4	irwd	Deferred Tax Assets Collaboration Agreement DeferredTaxAssetsCollaborationAgreement	48594000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	6114000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	6415000
CY2020Q4	irwd	Deferred Tax Assets Convertible Senior Notes DeferredTaxAssetsConvertibleSeniorNotes	6183000
CY2019Q4	irwd	Deferred Tax Assets Convertible Senior Notes DeferredTaxAssetsConvertibleSeniorNotes	4322000
CY2020Q4	irwd	Deferred Tax Assets Interest Expense DeferredTaxAssetsInterestExpense	3386000
CY2019Q4	irwd	Deferred Tax Assets Interest Expense DeferredTaxAssetsInterestExpense	22020000
CY2020Q4	irwd	Deferred Tax Assets Operating Leases DeferredTaxAssetsOperatingLeases	6504000
CY2019Q4	irwd	Deferred Tax Assets Operating Leases DeferredTaxAssetsOperatingLeases	6421000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5049000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5295000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	414590000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	452806000
CY2020Q4	irwd	Deferred Tax Liabilities Convertible Senior Notes2024 DeferredTaxLiabilitiesConvertibleSeniorNotes2024	5951000
CY2019Q4	irwd	Deferred Tax Liabilities Convertible Senior Notes2024 DeferredTaxLiabilitiesConvertibleSeniorNotes2024	7381000
CY2020Q4	irwd	Deferred Tax Liabilities Convertible Senior Notes2026 DeferredTaxLiabilitiesConvertibleSeniorNotes2026	9022000
CY2019Q4	irwd	Deferred Tax Liabilities Convertible Senior Notes2026 DeferredTaxLiabilitiesConvertibleSeniorNotes2026	10276000
CY2020Q4	irwd	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	4603000
CY2019Q4	irwd	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	4905000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	19576000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	22562000
CY2020Q4	irwd	Deferred Tax Assets Net Including Valuation Allowances DeferredTaxAssetsNetIncludingValuationAllowances	395014000
CY2019Q4	irwd	Deferred Tax Assets Net Including Valuation Allowances DeferredTaxAssetsNetIncludingValuationAllowances	430244000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	395014000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	430244000
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	395000000.0
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	430200000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-35200000
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-29100000
CY2020Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	65300000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	53099000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	38551000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	24078000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	66687000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	51699000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	38551000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1400000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	51699000
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	38551000
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	24078000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	68087000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	53099000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	38551000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	68100000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	53100000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	38600000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	68100000
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	800000
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	800000
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020	irwd	Defined Contribution Plan Employer Matching Contribution Employee Contribution Percent DefinedContributionPlanEmployerMatchingContributionEmployeeContributionPercent	0.75
CY2020	irwd	Defined Contribution Plan Employer Matching Contribution Employee Contribution Maximum DefinedContributionPlanEmployerMatchingContributionEmployeeContributionMaximum	6000
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1800000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2200000
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3200000
CY2020	us-gaap	Restructuring Charges RestructuringCharges	15400000
CY2019	us-gaap	Restructuring Charges RestructuringCharges	3600000
CY2018	us-gaap	Restructuring Charges RestructuringCharges	14700000
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79943000
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	89432000
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	103468000
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	116680000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	389523000
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	66716000
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	56719000
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	57852000
CY2020Q4	us-gaap	Costs And Expenses CostsAndExpenses	65296000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	246583000
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9882000
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7509000
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9804000
CY2020Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6884000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-34079000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	3345000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	25204000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	34423000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	43204000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	106176000
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.16
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.22
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.67
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.16
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.21
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.66
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	68730000
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	102215000
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	131167000
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	126301000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	428413000
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	85663000
CY2019Q2	us-gaap	Costs And Expenses CostsAndExpenses	80638000
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	65280000
CY2019Q4	us-gaap	Costs And Expenses CostsAndExpenses	76709000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	308290000
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4912000
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9294000
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-45239000
CY2019Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1735000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-61180000
CY2019Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-21846000
CY2019Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	12283000
CY2019Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	20648000
CY2019Q4	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	47858000
CY2019	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	58943000
CY2019Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-37438000
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-37438000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-59284000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	12283000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	20648000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	47858000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	21505000
CY2019Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.14
CY2019Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.08
CY2019Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.13
CY2019Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.31
CY2019	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.38
CY2019Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.14
CY2019Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.08
CY2019Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.13
CY2019Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.30
CY2019	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.38
CY2019Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.24
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.24
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.30
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2020	us-gaap	Restructuring Charges RestructuringCharges	15400000
CY2020	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-6100000
CY2019	us-gaap	Restructuring Charges RestructuringCharges	3600000
CY2019Q2	irwd	Gain Loss On Modification Of Lease GainLossOnModificationOfLease	3200000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-31000000.0
CY2019	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	3000000.0

Files In Submission

Name	View Source	Status
0001558370-21-001136-index-headers.html	Edgar Link	pending
0001558370-21-001136-index.html	Edgar Link	pending
0001558370-21-001136.txt	Edgar Link	pending
0001558370-21-001136-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
irwd-20201231.xsd	Edgar Link	pending
irwd-20201231x10k.htm	Edgar Link	pending
irwd-20201231x10k002.jpg	Edgar Link	pending
irwd-20201231x10k_htm.xml	Edgar Link	completed
irwd-20201231xex10d13d1.htm	Edgar Link	pending
irwd-20201231xex23d1.htm	Edgar Link	pending
irwd-20201231xex31d1.htm	Edgar Link	pending
irwd-20201231xex31d2.htm	Edgar Link	pending
irwd-20201231xex32d1.htm	Edgar Link	pending
irwd-20201231xex32d2.htm	Edgar Link	pending
irwd-20201231xex4d5.htm	Edgar Link	pending
irwd-20201231_cal.xml	Edgar Link	unprocessable
irwd-20201231_def.xml	Edgar Link	unprocessable
irwd-20201231_lab.xml	Edgar Link	unprocessable
irwd-20201231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R132.htm	Edgar Link	pending
R133.htm	Edgar Link	pending
R134.htm	Edgar Link	pending
R135.htm	Edgar Link	pending
R136.htm	Edgar Link	pending
R137.htm	Edgar Link	pending
R138.htm	Edgar Link	pending
R139.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R140.htm	Edgar Link	pending
R141.htm	Edgar Link	pending
R142.htm	Edgar Link	pending
R143.htm	Edgar Link	pending
R144.htm	Edgar Link	pending
R145.htm	Edgar Link	pending
R146.htm	Edgar Link	pending
R147.htm	Edgar Link	pending
R148.htm	Edgar Link	pending
R149.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R150.htm	Edgar Link	pending
R151.htm	Edgar Link	pending
R152.htm	Edgar Link	pending
R153.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd

2019 Q4 Form 10-K Financial Statement

#000155837021001136 Filed on February 17, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRWD IRONWOOD PHARMACEUTICALS INC Stock $irwd

2019 Q4 Form 10-K Financial Statement

#000155837021001136 Filed on February 17, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd